Examining the Nocebo Effect in Trials of Neuromodulators for Use in Disorders of Gut-Brain Interaction.

Jeremy Romek Glissen BrownAva SanayeiSamantha ProctorRyan FlanaganSarah BallouPaul A BainJudy Nee

Published in: The American journal of gastroenterology (2023)

Patients with DGBI in RCT randomized to placebo groups frequently experience AE and AE that lead to withdrawal consistent with a strong nocebo effect. Nonspecific AE such as dizziness, headaches, and diarrhea occurred similarly in patients receiving placebo compared with those receiving neuromodulators.

Keyphrases

double blind
phase iii
placebo controlled
open label
randomized controlled trial
resting state
brain injury
study protocol
clostridium difficile